Medicine and Dentistry
Ankylosing Spondylitis
50%
Body Weight
20%
C Reactive Protein
17%
Cohort Analysis
100%
Cohort Study
10%
Disease Activity
60%
Drug Dose Regimen
50%
Drug Megadose
10%
Drug Response
50%
Drug Therapy
50%
Infection
14%
Internal Medicine
7%
Low Drug Dose
10%
Prednisolone
17%
Psoriatic Arthritis
100%
Rheumatic Disease
24%
Rheumatoid Arthritis
50%
Rheumatology
70%
TNF Inhibitor
60%
Treatment Response
50%
Pharmacology, Toxicology and Pharmaceutical Science
Adalimumab
35%
Ankylosing Spondylitis
50%
C Reactive Protein
17%
Cohort Study
72%
Disease Activity
72%
Disease Duration
22%
Etanercept
47%
Infection
10%
Infliximab
47%
Prednisolone
17%
Psoriatic Arthritis
100%
Rheumatic Disease
10%
Rheumatoid Arthritis
50%
Tumor Necrosis Factor Inhibitor
100%
Keyphrases
41 Countries
16%
ACR20
20%
ACR50
10%
BASFI
8%
BASMI
8%
Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)
16%
Case-based Discussion
12%
Clinical Competence
16%
Curriculum Vitae
12%
Dosing Regimen
50%
European Harmonization
16%
European League against Rheumatism (EULAR)
10%
European Union of Medical Specialists
10%
General Internal Medicine
8%
High Body Weight
10%
Individual Competence
16%
Inhibitor Agent
25%
Internal Medicine Training
8%
International Training
10%
Kaplan-Meier Plot
10%
Knowledge Professionals
10%
Length Structure
8%
Lower Starting Dose
10%
Multisource Feedback
12%
Non-rheumatoid
9%
Online Voting
10%
Personal Development Plan
12%
Postgraduate Learning
12%
Psoriatic Arthritis
50%
Rheumatologic
10%
Rheumatology Care
10%
Rheumatology Research
10%
Rheumatology Training
8%
Specialty Training Programme
50%
Starting Dose
10%
Swollen Joint Count
10%
Tobacco-related Diseases
8%
Training Length
8%
Treatment Switching
25%
